Newsletters

  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
All
  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
R&D Insight

WHO pipeline reviews: Antifungal agents and fungal diagnostics

Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current
Read More >
R&D Insight

Now live: HERA’s call for rapid point-of-care susceptibility devices

Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The
Read More >
R&D Insight

Updates: CARB-X TPPs; Independent Panel for Evidence for Action against AMR

Dear All, Two quick updates this evening. First, you will recall that CARB-X have announced their initial 2025 funding round
Read More >
R&D Insight

Unexpected resistance: The tale of rifaximin and daptomycin

Dear All (and with thanks to Patricia Bradford for taking the lead on this newsletter): Today, this paper in Nature
Read More >
R&D Insight

CARB-X announces its 2025 funding round

Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two
Read More >
R&D Insight

Ineos Oxford Institute for AMR seeks Director

Dear All, I have learned that the Ineos Oxford Institute for Antimicrobial Research (IOI) has started a job search for
Read More >
R&D Insight

HERA: 13m EUR call for rapid point-of-care susceptibility devices

24 Mar 2025 update: The call is live! It’s entitled “Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical
Read More >
R&D Insight

EMA: 16m EUR to fund regulatory science research

Dear All, EMA have recently posted a call for tenders under which they seek to “procure the services of research
Read More >
R&D Insight

Sign-on Letter to Preserve Upcoming ACIP Meeting

Dear All, The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet 26-28 Feb 2025 (see links below my signature
Read More >
R&D Insight

ESCMID 2025: Science Policy Forum and Pipeline Day events

Dear All, If you are attending ESCMID Global in Vienna this year, mark your calendar for two major events. I
Read More >
R&D Insight

Gates/Novo Nordisk/Wellcome Grand Challenge: Gr-ADI, the Gram-Negative Antibiotic Discovery Innovator

Dear All, A huge announcement today backed by the combined power of the Gates Foundation, Novo Nordisk, and Wellcome! I
Read More >
R&D Insight

Jan 2025 PACCARB meeting cancelled as new administration takes the reins

Dear All, Sadly, I must report that the 27th meeting of PACCARB (the US Presidential Advisory Council on Combatting Antibiotic-Resistant
Read More >
R&D Insight

NOHF-Zoonoses, NARMS, and more: US action on One Health, Surveillance, and much more

Dear All, Three things for today along with some great acronyms! To start, we have an announcement of the first
Read More >
R&D Insight

Italy delivers a national pull incentive (with a budget of EUR 100 million a year)!

Dear All (and with thanks to Damiano for taking the lead on this newsletter), We start the new year with good
Read More >
R&D Insight

WHO-GARDP: Policy interventions for (mostly acute) antibiotic shortages

Dear All, I wrote in the 1 Dec 2024 newsletter about the excellent paper by Baraldi et al. that introduced
Read More >
R&D InsightWonkish

Mirror Bacteria: An AMR threat of unprecedented magnitude

Dear All (wonkish but stick with it … I’m going to try very hard to de-wonk it), In an absolutely
Read More >
R&D Insight

(Re)using surveillance data: 2024 Vivli Challenge Awardees

Dear All, I’ve written before about the Vivli AMR Surveillance Data Challenge that seeks creative ways to reuse MICs from surveillance
Read More >
Government ActionSomething Different

The 6 meanings of “Lack of Access” (UNSLAP)

Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we
Read More >
R&D Insight

NIAID/DMID call for antibacterials, antifungals, vaccines, & diagnostics

Dear All, Just released, the 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications for projects to treat, prevent,
Read More >
Government ActionPush/Pull

Sign a letter to help #PassPASTEUR!

Dear All,  MyCARE, a fungal patient advocacy organization, and the Partnership to Fight Infectious Diseases (PFID), are sending a letter
Read More >
Scroll to Top